[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Impact Factor 2022: 1.4
Cite Score 2022: 2.1
SJR 2022: 0.347
SNIP 2022: 0.545
Publication Charge
►Publication Fee
In Press
 In Press Articles
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 14, Issue 1 (Winter 2023) ::
Caspian J Intern Med 2023, 14(1): 76-82 Back to browse issues page
Could melatonin prevent vancomycin-induced nephrotoxicity in critically ill patients? A randomized, double-blinded controlled trial
Saeid Abbasi , Ehsan Bigharaz , Shadi Farsaei , Marjan Mansourian
Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran , farsaei@pharm.mui.ac.ir
Abstract:   (1607 Views)
Background: Previous researche showed some clinical benefits regarding the nephroprotective effect of melatonin. So, this study aimed to evaluate the beneficial effect of oral melatonin on preventing acute kidney injury (AKI) in patients who received vancomycin therapy in the intensive care unit (ICU).
Methods: We performed a randomized, double-blinded, placebo-controlled pilot study in an academic hospital. Adult patients admitted to the ICU who received vancomycin with normal gastrointestinal and kidney function were randomized into treatment or placebo groups. After that, enrolled patients received a tablet of melatonin (3 mg) or placebo twice daily for seven consecutive days.
 The occurrence of AKI was assessed by RIFLE criteria (by measurement of serum creatinine (SCr)) and plasma neutrophil gelatinase-associated lipocalin (NGAL) concentration. Moreover, other data related to renal functions and SOFA were also compared between groups.
Results: A total of 90 patients were included in the study, while 21patients in the placebo group and 20 in the intervention group completed the study. There were no significant differences between groups regarding baseline SCr, BUN, urine output, NGAL, SOFA, and glomerular filtration rate (GFR). Our results showed that these differences remained insignificant after a 7-day follow-up between groups. However, the incidence of AKI was significantly lower in the melatonin group based on the NGAL cutoff (> 150 ng/mL).
Conclusion: We detected a significant decrease in vancomycin-induced nephrotoxicity incidence in patients receiving melatonin compared to placebo. However, more clinical trials in a larger population were required to confirm this result.
Keywords: Melatonin, Vancomycin, Acute Kidney Injury, Intensive Care Units
Full-Text [PDF 263 kb]   (610 Downloads)    
Type of Study: Original Article | Subject: Nephrology
Received: 2021/12/27 | Accepted: 2022/02/19 | Published: 2023/01/21
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abbasi S, Bigharaz E, Farsaei S, mansourian M. Could melatonin prevent vancomycin-induced nephrotoxicity in critically ill patients? A randomized, double-blinded controlled trial. Caspian J Intern Med 2023; 14 (1) :76-82
URL: http://caspjim.com/article-1-3291-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 1 (Winter 2023) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.05 seconds with 40 queries by YEKTAWEB 4645